- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 25.02. | 15 States sue HHS over changes to childhood vaccine schedule | ||
| 25.02. | With Vivtex deal, Novo gains a chance at better oral obesity drugs | ||
| 25.02. | BreezeBio banks $60M to make more precise genetic medicines | ||
| 24.02. | Vir climbs on Astellas deal, study results for 'masked' T cell engager | ||
| 24.02. | Novo to cut GLP-1 drug prices; Palvella soars on study data | ||
| 24.02. | Novo, searching for a spark, spotlights new data for three-pronged obesity drug | ||
| 24.02. | Slate starts up with $130M and a headache drug from China | ||
| 23.02. | FDA fleshes out new roadmap for testing personalized therapies | ||
| 23.02. | Novo's next-gen obesity shot fails to match Lilly drug in head-to-head study | ||
| 23.02. | Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy | ||
| 23.02. | Merck to split cancer, specialty drug businesses in leadership shakeup | ||
| 23.02. | All about cell therapy process characterization | ||
| 23.02. | Small and mighty: single-domain antibodies pack a biological punch | ||
| 20.02. | Grail's multi-cancer early detection test misses study goal | ||
| 20.02. | Supreme Court invalidates Trump tariffs based on emergency powers | ||
| 20.02. | Roche gets FDA decision date on closely watched breast cancer drug | ||
| 20.02. | Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi | ||
| 20.02. | AI is slashing jobs across industries. Will pharma be next? | ||
| 19.02. | Altesa, run by former Trump official, raises $75M for well-traveled lung drug | ||
| 19.02. | FDA leaders say one pivotal trial, not two, should be 'default' for drug approvals | ||
| 18.02. | Lilly to pay CSL $100M to license monoclonal antibody targeting IL-6 | ||
| 18.02. | An Alzheimer's startup emerges with $175M in venture backing | ||
| 18.02. | Psychedelics stocks rise as Compass' psilocybin drug heads to FDA | ||
| 18.02. | FDA reverses course on Moderna's flu vaccine | ||
| 18.02. | FDA accepts BMS protein degrader for review; Disc rare disease drug rejected |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.